Therapeutic strategies in epithelial ovarian cancer.

Journal of Experimental & Clinical Cancer Research : CR
Ayako KimTakayuki Enomoto

Abstract

Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway.

References

Oct 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanW Hoskins
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S B KayeJ Kavanagh
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S ChanUNKNOWN 303 Study Group
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M MuggiaJ M Small
Feb 13, 2001·British Journal of Cancer·P A VaseyS B Kaye
Jan 17, 2003·Journal of the National Cancer Institute·J Baptist TrimbosUNKNOWN European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm
Oct 25, 2003·Science·Mary-Claire KingUNKNOWN New York Breast Cancer Study Group
Apr 28, 2004·The American Journal of Pathology·Ie-Ming Shih, Robert J Kurman
Nov 18, 2004·Journal of the National Cancer Institute·Paul A VaseyUNKNOWN Scottish Gynaecological Cancer Trials Group
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E JonesP M Ravdin
Jan 6, 2006·The New England Journal of Medicine·Deborah K ArmstrongUNKNOWN Gynecologic Oncology Group
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Oct 10, 2008·Annual Review of Pathology·Kathleen R Cho, Ie-Ming Shih
Nov 29, 2008·The Lancet Oncology·Louis Dubeau
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Oct 2, 2009·Lancet·Bryan T HennessyMaurie Markman
Feb 16, 2010·The American Journal of Surgical Pathology·Robert J Kurman, Ie-Ming Shih
Feb 23, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Satoshi TakakuraUNKNOWN Japanese Gynecologic Oncology Group
Mar 5, 2010·Nature Reviews. Cancer·Michèle RouleauGuy G Poirier
Apr 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter C FongStan B Kaye
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineAndreas du Bois
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkAndrés M Poveda
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Sep 8, 2010·The New England Journal of Medicine·Ignace VergoteUNKNOWN NCIC Clinical Trials Group
Mar 1, 2011·Cancer Letters·Sandro PignataGaetano Facchini
May 4, 2011·World Journal of Biological Chemistry·Hiroaki Itamochi
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group
Dec 30, 2011·The New England Journal of Medicine·Timothy J PerrenUNKNOWN ICON7 Investigators

❮ Previous
Next ❯

Citations

Oct 3, 2013·Cancer Chemotherapy and Pharmacology·Michalis AlevizakosKonstantinos N Syrigos
Aug 28, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuanyuan FangShulan Zhang
Mar 20, 2013·BioMed Research International·Qinglei ZhanSaiming Ngai
Dec 11, 2013·Journal of Experimental & Clinical Cancer Research : CR·Da LiQing Yang
Jan 1, 2014·Environmental Toxicology and Pharmacology·Agnieszka MarczakAneta Rogalska
Feb 11, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Jiasheng WangFrederick T Greenaway
Nov 30, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuling CuiZihan Sun
Oct 9, 2014·BMC Complementary and Alternative Medicine·Tenzin ChoedonVijay Kumar
Jan 15, 2016·Journal of Experimental & Clinical Cancer Research : CR·Xiaochun SunHongye Zhang
Jan 6, 2016·Journal of Experimental & Clinical Cancer Research : CR·Wenting XuNonghua Lu
Dec 30, 2014·Journal of Experimental & Clinical Cancer Research : CR·Ying WuKimitoshi Kohno
Sep 18, 2014·Journal of Experimental & Clinical Cancer Research : CR·Cinzia TesauroAlessandro Desideri
May 28, 2014·Journal of Ovarian Research·Gerasimos Aravantinos, Dimitrios Pectasides
Aug 1, 2015·Journal of Ovarian Research·Yueping ZhanXiangdong Kang
Aug 5, 2015·Journal of Experimental & Clinical Cancer Research : CR·Zhongping ChengXiaoyan Qu
Apr 30, 2014·Journal of Experimental & Clinical Cancer Research : CR·Evandro Luís NieroGláucia Maria Machado-Santelli
Aug 10, 2013·Journal of Experimental & Clinical Cancer Research : CR·Patrizia ViciLuigi Di Lauro
Jan 23, 2015·Cancer Science·Takahiro YamaguchiHiroto Izumi
Sep 1, 2015·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Jyun-Yi LinTsing-Fen Ho
Jul 8, 2015·Endocrine-related Cancer·Yu-Li ChenWen-Fang Cheng
May 15, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Swapnil S DesaleTatiana K Bronich
Mar 5, 2015·Cancer Metastasis Reviews·Mohamed A Elzek, Karin D Rodland
May 11, 2016·Radiographics : a Review Publication of the Radiological Society of North America, Inc·Venkata S KatabathinaSrinivasa R Prasad
May 31, 2016·Journal of the Egyptian National Cancer Institute·Mohamed Elshebeiny, Walid Almorsy
Sep 8, 2016·Bioorganic & Medicinal Chemistry Letters·Yusuke OgitaniToshinori Agatsuma
Sep 7, 2016·Journal of Experimental & Clinical Cancer Research : CR·Peixin DongNoriaki Sakuragi
Dec 30, 2016·International Journal of Cancer. Journal International Du Cancer·Feng-Hsiang TangEing-Mei Tsai
Nov 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elisabeth MaritschneggRobert Zeillinger
Mar 22, 2016·Scientific Reports·Chaofu KeKang Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Related Papers

Nature Clinical Practice. Oncology
Thomas J Herzog, Bhavana Pothuri
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Gerald BatistArthur C Louie
Journal of Controlled Release : Official Journal of the Controlled Release Society
Hardeep S OberoiTatiana K Bronich
Dalton Transactions : an International Journal of Inorganic Chemistry
Nial J WheateRabbab Oun
© 2022 Meta ULC. All rights reserved